Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report released on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other analysts have also weighed in on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. HC Wainwright reiterated a “neutral” rating and issued a $6.60 price objective on shares of Revance Therapeutics in a research note on Friday, November 8th. Mizuho reduced their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research report on Tuesday, December 10th. Finally, Barclays reduced their price target on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Monday, December 23rd. Nine analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Revance Therapeutics currently has an average rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Stock Performance

NASDAQ:RVNC opened at $3.65 on Friday. The company has a fifty day moving average of $3.36 and a 200-day moving average of $4.57. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.56.

Hedge Funds Weigh In On Revance Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Alpine Associates Management Inc. purchased a new position in Revance Therapeutics during the 3rd quarter worth $21,605,000. Alliancebernstein L.P. boosted its holdings in Revance Therapeutics by 7.3% during the 4th quarter. Alliancebernstein L.P. now owns 3,497,112 shares of the biopharmaceutical company’s stock worth $10,631,000 after acquiring an additional 236,641 shares during the last quarter. Magnetar Financial LLC boosted its holdings in Revance Therapeutics by 2.2% during the 4th quarter. Magnetar Financial LLC now owns 2,556,345 shares of the biopharmaceutical company’s stock worth $7,771,000 after acquiring an additional 56,174 shares during the last quarter. State Street Corp boosted its holdings in Revance Therapeutics by 6.6% during the 3rd quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock worth $12,632,000 after acquiring an additional 150,323 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Revance Therapeutics by 0.3% during the 4th quarter. Geode Capital Management LLC now owns 2,297,582 shares of the biopharmaceutical company’s stock worth $6,986,000 after acquiring an additional 7,928 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.